Understanding the Impact of Chamber Deviations

Deviations in stability chambers, especially temperature and humidity excursions, can influence product quality, alter degradation profiles, and violate protocol compliance. The extent and duration of the deviation determine whether the data is still valid or compromised.

• ✅ Temperature excursions: Short-term fluctuations can sometimes be justified, especially if data loggers confirm minimal impact.
• ✅ Humidity failures: May affect hygroscopic products, requiring chemical and physical analysis to assess the impact.
• ✅ Equipment malfunction: Power failures, sensor faults, or door leakage can lead to non-conformances requiring immediate assessment.

Any deviation must be evaluated based on product risk, deviation duration, frequency, and type of chamber (e.g., ICH Zone II vs Zone IVb).

Root Cause Analysis (RCA) and CAPA Planning

Before proceeding with any justification, a documented root cause analysis (RCA) is essential. Using tools like fishbone diagrams or 5 Whys, determine what led to the excursion. Then, propose corrective and preventive actions (CAPA):

• ✅ Replace faulty sensors or recalibrate them
• ✅ Strengthen alarm systems and data logging review frequency
• ✅ Improve temperature/humidity mapping and trending

CAPA implementation ensures the issue is resolved and prevents recurrence, which strengthens the regulatory justification for data inclusion.

Justification Strategy: Scientific and Regulatory Alignment

A strong justification integrates scientific rationale with regulatory expectations. Use the following framework:

1. Describe the deviation: Start with time, nature, and cause (e.g., “Temperature rose to 32℃ for 3 hours due to compressor failure”).
2. Assess impact: Analyze if temperature/time combination likely impacted product degradation.
3. Reference stability data: Show prior real-time or accelerated studies support no loss of integrity.
4. Cross-check other batches: Demonstrate that similar batches in similar conditions showed no instability.

Refer to ICH Guidelines such as Q1A(R2) to support time-temperature excursion limits and justification protocols.

Supporting Data and Testing

Conduct retesting or additional assays to validate product performance if needed. This may include:

• ✅ Assay and impurity profile rechecking
• ✅ Dissolution testing (for orals)
• ✅ Visual appearance and pH
• ✅ Microbial testing if indicated

If all tests are within specification, results support the case for continuation without restarting the study.

Documentation and Audit Readiness

Your justification will only hold during an inspection if supported by structured documentation. This must include:

• ✅ Deviation report with RCA and CAPA
• ✅ Stability protocol reference and impacted batches
• ✅ Data from the environmental monitoring system
• ✅ QA approval and risk assessment reports

Maintain audit-ready records and internal approvals before proceeding with the justification letter to regulators.

Internal Reference: GMP deviation reporting

Writing a Regulatory Justification Letter

A regulatory justification letter must be written clearly and structured in line with GxP expectations. It should be signed by the Quality Head and supported by the site stability manager and technical experts. The letter should include the following:

• ✅ A detailed timeline of the deviation
• ✅ Environmental data log extracts showing deviation duration
• ✅ Risk assessment summary and product-specific impact evaluation
• ✅ Cross-reference to prior stability data and scientific rationale
• ✅ CAPA status and preventive steps
• ✅ Request for acceptance of existing data without repeating the study

Ensure the language is clear, non-defensive, and adheres to regulatory tone and format. Avoid vague justifications and always present data-driven reasoning.

Citing Guidelines and Precedents

In your justification, always cite applicable international guidance. Some commonly used references include:

• ✅ ICH Q1A(R2) – Stability testing principles
• ✅ FDA Guidance on Stability – Especially for temperature excursions
• ✅ WHO TRS 1010 – Covers impact assessment of deviation in tropical zones
• ✅ PIC/S deviation handling recommendations

Review similar deviation case studies and outcomes from past inspections to bolster your case.

Statistical Evaluation and Data Comparison

In cases where stability chambers deviate marginally, statistical tools can help assess if the data remains reliable:

• ✅ Use regression analysis to compare trend lines pre- and post-deviation
• ✅ Evaluate Mean Kinetic Temperature (MKT) to assess the net temperature impact
• ✅ Compare OOS/OOT trend with historical batch data

This approach helps avoid repeating studies unnecessarily and shows proactive quality decision-making.

When to Restart the Stability Study

There are cases where continuation is not advisable. You should consider restarting the study if:

• ❌ Deviation exceeded critical thresholds for an extended time (e.g., 48+ hours at 40°C/75%)
• ❌ Significant change observed in product appearance or assay
• ❌ Incomplete environmental data or gap in monitoring
• ❌ Regulatory agency requests study restart post-inspection

In such cases, a formal investigation must be closed, and a new study protocol should be initiated with better controls in place.

Audit and Inspection Preparedness

Auditors will scrutinize chamber deviation records and their resolutions. To stay audit-ready:

• ✅ Maintain deviation logs with real-time data
• ✅ Keep SOPs updated for deviation management and excursion handling
• ✅ Train staff on protocol adherence and deviation reporting
• ✅ Include deviation trend reports in annual product reviews (APR/PQR)

Mock inspections and internal QA walkthroughs can help ensure preparedness and uncover documentation gaps early.

Conclusion

Justifying the continuation of a stability study after a chamber deviation requires a multi-pronged approach: scientific, statistical, regulatory, and procedural. With proper documentation, data integrity assurance, and CAPA execution, pharmaceutical firms can navigate such deviations confidently—without compromising product safety or compliance.

For ongoing compliance, integrate chamber monitoring alerts, redundancy systems, and real-time dashboards to detect and respond to deviations immediately.

Remember: Every deviation is an opportunity to strengthen your quality system—not just a threat to stability data.

In GMP-compliant pharmaceutical and biotechnology environments, equipment deviations are a routine reality. Whether it’s a temperature spike in a stability chamber, a malfunctioning UV meter, or an out-of-calibration balance, the implications can be significant—particularly when stability data or product quality is impacted. An effective deviation impact assessment ensures that such events are not just documented but evaluated thoroughly for their risk, scope, and potential recurrence.

Regulators such as the USFDA and CDSCO expect that every deviation—especially those affecting equipment—must be subjected to a structured and science-based impact evaluation. This article walks through the must-have elements in such an assessment.

Identifying the Deviation and Trigger Event

The first step in the assessment is to define the exact nature of the deviation. This includes:

• ✅ Date and time of occurrence
• ✅ Affected equipment (e.g., Stability Chamber SC-03, UV Meter ID#A102)
• ✅ Triggering factor (e.g., sensor failure, power loss, calibration lapse)

A clear and traceable log entry should back the deviation, and supporting documentation such as equipment alarms, BMS alerts, or manual observations should be compiled immediately.

Assessing the Scope and Extent of Impact

The next critical step involves identifying which products, batches, or data points were affected. Questions to answer:

• ✅ Were any stability samples stored in the affected chamber during the deviation window?
• ✅ What time points or test parameters may have been compromised?
• ✅ Is there redundancy in monitoring (e.g., secondary data loggers)?

Include a detailed table of impacted batches, test parameters, and timelines. Referencing Clinical trial stability data or commercial lot numbers strengthens traceability and audit defense.

Risk Evaluation and Criticality Classification

Not all deviations have the same impact. The assessment must classify the deviation using a risk matrix:

Risk rating helps determine whether re-testing is necessary, whether data exclusion is justified, or whether regulatory notification is triggered.

Root Cause Analysis Techniques

A deviation impact assessment is incomplete without an RCA (Root Cause Analysis). Use tools such as:

• ✅ 5 Whys Analysis
• ✅ Fishbone (Ishikawa) Diagram
• ✅ Fault Tree Analysis (FTA)

The RCA must differentiate between human error, equipment failure, systemic gaps, and process deficiencies. Remember, regulators do not accept “inconclusive” as a final root cause unless justified with proof of exhaustive investigation.

Corrective and Preventive Actions (CAPA)

Once the root cause is established, corrective and preventive actions must be proposed and tracked. For equipment deviations, these may include:

• ✅ Equipment servicing or recalibration
• ✅ Alarm system validation
• ✅ Staff training and retraining
• ✅ Enhancing SOPs for monitoring and documentation

Each CAPA item should have a responsible person, timeline, and effectiveness check plan. This also ensures readiness during GMP audits.

Documentation and Deviation Report Format

A well-documented deviation impact assessment is a powerful defense during inspections. At a minimum, the report must include:

• ✅ Deviation number and date
• ✅ Description and triggering event
• ✅ Impact analysis (including tables, figures, timelines)
• ✅ Root cause analysis method and findings
• ✅ CAPA plan with responsible functions
• ✅ QA review and approval

All attachments—alarms, logs, emails, raw data—should be linked digitally or appended physically, and stored in accordance with data integrity principles.

QA Review and Final Closure

The QA team plays a pivotal role in reviewing the assessment and determining if the deviation warrants requalification, reporting to health authorities, or stability data exclusion. Their checklist may include:

• ✅ Were similar deviations reported in the past 6 months?
• ✅ Was the deviation categorized correctly (critical, major, minor)?
• ✅ Were stability samples evaluated adequately?
• ✅ Is the CAPA sufficient to prevent recurrence?

The QA sign-off is not a formality—it must reflect critical analysis and regulatory expectations.

Trending and Recurrence Tracking

Effective deviation systems go beyond one-time resolution. They analyze recurrence trends using tools such as:

• ✅ Deviation dashboards
• ✅ Equipment-specific failure logs
• ✅ Calendar-based risk mapping

Trends help in identifying if certain stability chambers, HVAC systems, or temperature sensors repeatedly cause problems. This leads to better budgeting for upgrades and preventive maintenance.

Regulatory Expectations and Global Examples

Agencies like the EMA and ICH expect companies to maintain transparent and risk-based deviation procedures. For example:

• ✅ ICH Q10 emphasizes pharmaceutical quality systems and deviation handling
• ✅ USFDA 483s have cited companies for failing to assess equipment failure impact on stability data
• ✅ ANVISA audits highlight lack of root cause documentation as a frequent non-conformance

Learning from global examples helps tailor site-level SOPs to withstand scrutiny and protect product quality.

Final Checklist Before Deviation Closure

Before closing an equipment-related deviation, ensure:

• ✅ Impact to product, process, or stability data is fully assessed
• ✅ Root cause is logical and data-supported
• ✅ CAPAs are implemented and verified
• ✅ QA approval is documented
• ✅ Documentation is archived as per GMP

Companies that follow this checklist reduce the likelihood of repeated issues and build robust regulatory confidence.

Conclusion

Deviation impact assessments for GMP equipment are more than routine paperwork—they are risk management tools that ensure data integrity, patient safety, and regulatory trust. A well-conducted assessment, backed by scientific analysis, documentation, and QA oversight, is your best protection during inspections and audits. Pharmaceutical manufacturers and CROs must prioritize training, SOP development, and cross-functional involvement in deviation handling. Remember, in the eyes of the regulator, a minor deviation ignored today is a major non-compliance tomorrow.

✅ What Are Equipment Deviations in Stability Testing?

Equipment deviations refer to any unexpected malfunction, out-of-specification reading, or non-conformance associated with qualified equipment used during stability testing. These events can arise from poor maintenance, calibration issues, sensor failure, software bugs, or human error.

Common categories include:

• ✅ Temperature or humidity excursions
• ✅ Calibration failure of data loggers or sensors
• ✅ Alarm system malfunction
• ✅ Power interruptions affecting data continuity
• ✅ Door seal damage or improper closure

✅ Deviation Example 1: Temperature Excursion in Stability Chamber

Scenario: A stability chamber set at 25°C/60% RH registered a temperature of 30.5°C for 4 hours due to HVAC malfunction over a weekend.

Detection: On Monday morning, the data logger review indicated out-of-spec readings between 2:00 AM and 6:00 AM on Sunday.

Immediate Action:

• ✅ Isolate the affected chamber
• ✅ Retrieve temperature and humidity logs
• ✅ Notify QA and initiate deviation form

Corrective Action: HVAC unit was replaced, and alarm triggers were enhanced to escalate alerts beyond facility hours via SMS. Retesting was done on impacted batches.

Regulatory Note: If the product is under registration, a notification may be warranted to USFDA or EMA depending on impact assessment.

✅ Deviation Example 2: Sensor Calibration Failure

Scenario: During routine monthly calibration, a temperature sensor showed a ±2°C deviation from the NIST-traceable standard.

Impact: The sensor had been in use without recalibration for 30 days in a 40°C/75% RH chamber.

Corrective Actions:

• ✅ All data for the affected period were flagged for review
• ✅ Historical excursions and degradation trends were analyzed
• ✅ A deviation report was filed, and a risk assessment concluded data acceptability based on minimal deviation
• ✅ Preventive action included reducing calibration intervals for high-traffic equipment

GMP compliance requires that calibration records be traceable and available for audits. Sensor drift should always trigger a thorough investigation.

✅ Deviation Example 3: Humidity Controller Malfunction

Scenario: A 30°C/65% RH chamber reported humidity at 40% RH for over 6 hours before returning to normal range.

Root Cause: The desiccant refill cycle was missed due to a system scheduling glitch.

Corrective Measures:

• ✅ Schedule validation was reprogrammed and checked
• ✅ QA reviewed degradation profiles of exposed samples
• ✅ An external audit-ready report was prepared for traceability

Refer to ICH Q1A(R2) for acceptable excursion windows and conditions for valid data retention.

✅ Deviation Example 4: Power Outage and Data Logger Failure

Scenario: A sudden power outage led to failure in the data logger monitoring a 25°C/60%RH stability chamber. The chamber resumed operation within 20 minutes, but environmental data were not recorded during this period.

Investigation: QA observed that the logger did not have a battery backup and no secondary logger was installed. Stability batches stored during that window were under evaluation for long-term studies.

Corrective Actions:

• ✅ Replace all data loggers with models having internal battery backup and alert functions
• ✅ Introduce dual logging for redundancy in all primary chambers
• ✅ Establish an SOP for rapid manual data entry during logger replacement
• ✅ Implement a protocol for estimating excursion impact using adjacent time-point data

This case highlights the importance of equipment qualification and disaster recovery SOPs during unexpected utility failures.

✅ Deviation Example 5: Calibration Lapse for Relative Humidity Sensor

Scenario: During a routine internal audit, it was discovered that one of the relative humidity (RH) sensors used in a 30°C/65%RH chamber was overdue for calibration by 3 months.

Impact Assessment: RH deviations were not detected because the primary sensor had drifted gradually. Secondary sensor comparison showed a deviation of 3% RH.

Corrective Actions:

• ✅ Recalibrate the RH sensor and flag the asset in the equipment management system
• ✅ Review all stability data during the deviation period and evaluate outliers
• ✅ Conduct a retrospective risk analysis using the sensor drift profile
• ✅ Trigger a CAPA to include automated calibration due alerts and cross-checking by QA

✅ Deviation Example 6: Temperature Spike Due to Overloaded Chamber

Scenario: A new product batch was introduced into a 40°C/75%RH chamber already at 85% loading capacity. This caused a temporary spike in internal temperature exceeding 42°C for 90 minutes.

Investigation: The chamber’s air circulation was not adequate for the increased load. No pre-loading thermal mapping was conducted to validate spatial uniformity under full load.

Corrective Actions:

• ✅ Redesign chamber loading SOPs with maximum allowable capacity
• ✅ Perform load mapping during qualification and document results
• ✅ Train operators on thermal dynamics and chamber balance
• ✅ Split large batches into staggered loads across validated chambers

Proper loading practices and periodic thermal mapping are part of global regulatory expectations including those outlined by ICH.

✅ Lifecycle of a Deviation: From Identification to CAPA Closure

Every deviation must follow a documented process to ensure traceability, accountability, and continuous improvement. The lifecycle typically includes:

• ✅ Identification and classification (critical, major, minor)
• ✅ Preliminary impact assessment
• ✅ Root cause analysis using tools like Fishbone or 5-Whys
• ✅ Corrective action and effectiveness verification
• ✅ Preventive action to eliminate recurrence
• ✅ Final QA sign-off and closure in the deviation log

Firms should ensure that all GMP compliance systems support automated tracking, escalation, and deviation trending for effective quality oversight.

✅ Final Thoughts

Equipment deviations are inevitable in long-term stability programs, but what differentiates high-compliance organizations is their preparedness and documentation. Real-time monitoring, well-trained staff, validated systems, and responsive CAPA implementation form the backbone of a robust stability infrastructure. Incorporating lessons from past deviations and sharing case studies across cross-functional teams ensures proactive control and continuous GMP alignment.

With the rising expectations of global regulators like the USFDA and EMA, pharmaceutical companies must embed equipment reliability and deviation traceability into their quality culture. Every excursion, however small, is an opportunity to strengthen the system.

In pharmaceutical stability testing, Out of Specification (OOS) results are red flags that demand immediate investigation. However, what follows is just as critical: linking these findings to robust Corrective and Preventive Actions (CAPA). This bridge ensures that the root cause isn’t just found, but fixed 🛠. Regulatory agencies like USFDA expect companies to demonstrate this link to prevent repeat deviations, safeguard product integrity, and maintain GMP compliance.

📝 Step 1: Conduct a Structured OOS Investigation

The OOS handling process typically follows a phased approach. For a meaningful CAPA, each phase must be documented and traceable.

1. Phase I – Laboratory Error Evaluation: Identify any calculation mistakes, analyst bias, or equipment failure. Document findings in the analyst worksheet.
2. Phase II – Full Investigation: If no lab error is found, escalate to manufacturing, packaging, storage or transport issues.
3. Root Cause Analysis (RCA): Use tools like 5 Whys, Fishbone Diagram, or Fault Tree Analysis. Each finding should clearly identify a system or process gap.

Without a clear root cause, the CAPA will remain weak and non-actionable ⛔.

📋 Step 2: Mapping Findings to CAPA Elements

Once the RCA is finalized, it must flow logically into a CAPA document. This includes:

• ✅ Corrective Action: Immediate fix to prevent recurrence (e.g., retraining, equipment calibration)
• ✅ Preventive Action: Long-term process improvement (e.g., revise SOPs, update analytical method)
• ✅ Action Owners: Assign clear responsibility with timelines
• ✅ Effectiveness Checks: Include a plan to monitor results (e.g., trend analysis for 3 future batches)

Ensure traceability by referencing the original OOS ID and investigation number in the CAPA form.

📦 Common Pitfalls in OOS to CAPA Transition

Many pharma firms struggle with this linkage due to:

• ❌ Generic CAPAs that do not address the real issue
• ❌ Missing root cause justification
• ❌ No timelines or responsibility assignment
• ❌ Over-reliance on retraining as a fix

Auditors from Pharma GMP or WHO expect documented evidence that every CAPA is risk-based, not checkbox-driven.

📊 Use a CAPA Mapping Table for Clarity

A CAPA mapping table ensures that every part of the OOS investigation translates into a clear action plan. Here’s a simplified format:

Using such tables makes audits smoother and helps regulatory reviewers understand your thought process.

🧐 Regulatory Expectations from Agencies

Regulatory bodies such as ICH expect CAPAs to not only address stability-specific issues but also system-wide weaknesses:

• 🔎 ICH Q10 requires Quality Systems to include deviation management and effectiveness reviews
• 🔎 ICH Q9 mandates a risk-based approach to CAPA implementation
• 🔎 USFDA warning letters often cite failure to link OOS with long-term actions

🔨 Implementing the CAPA: A Step-by-Step Workflow

Once the CAPA plan is documented, execution must follow a traceable and auditable trail. Here’s how to implement it effectively:

1. Kick-off Meeting: Bring together QA, QC, Production, and Engineering to discuss the CAPA scope.
2. Timeline Planning: Use a Gantt chart to assign and track deadlines. Prioritize high-risk deviations.
3. Execution: Ensure each action item (SOP revision, instrument requalification, personnel training) is completed as per plan.
4. Documentation: Upload proof of implementation into your Quality Management System (QMS). Include updated logs, training records, and change controls.
5. CAPA Closure: QA should verify completion and effectiveness of each action before formally closing it.

⛽ Real-World Example: CAPA from OOS in Stability Study

Scenario: A product stored at 30°C/75%RH showed a significant drop in dissolution at 12 months. The OOS was confirmed and traced back to packaging permeability.

• 📝 Root Cause: Outer carton material failed to maintain humidity barrier.
• ✅ Corrective Action: Replace packaging lot, recall impacted batches, and update supplier spec.
• ✅ Preventive Action: Introduce carton integrity testing during incoming QC and perform stability studies with new packaging.
• 👨‍🎓 Owner: Head of Procurement and QA
• 📦 Timeline: All actions to be completed within 30 days and effectiveness to be reviewed over next 3 batches.

📚 Tools to Strengthen Your OOS-to-CAPA Program

• ⚙️ QMS Software: Automates OOS-CAPA linkage and maintains audit trail
• 📄 Deviation Templates: Standardize documentation across teams
• 📊 Risk Ranking Matrix: Helps prioritize CAPAs based on impact
• 💻 Audit Checklists: Prepares QA to demonstrate linkage to regulatory inspectors

Platforms like Pharma Validation offer tools and validation templates tailored for these integrations.

🛈 SOP Guidelines for Linking OOS and CAPA

Your SOPs should explicitly mention:

• 📝 When CAPA is required for an OOS
• 📝 Format of linking investigation number to CAPA form
• 📝 How to escalate if OOS is repeated in future lots
• 📝 Who signs off CAPA closure and where the documentation is archived

Periodic SOP reviews (e.g., every 2 years) are recommended as per CDSCO guidelines.

🎯 CAPA Effectiveness Review: The Final Step

No CAPA process is complete without verifying that it worked. Effectiveness checks may include:

• 📈 Review of next 3–5 stability batches
• 📈 Repeat audit or walkthrough
• 📈 Statistical trending reports (e.g., reduced frequency of similar deviations)
• 📈 Periodic QA review meetings with closure summaries

Failure to perform this step results in recurring deviations—one of the top FDA 483 observations in the past 5 years.

🏆 Final Thoughts

Incorporating a solid OOS to CAPA linkage is not just good practice—it’s a regulatory expectation. By clearly defining responsibilities, using structured formats, and closing the loop through effectiveness reviews, pharmaceutical companies can protect product quality and build audit readiness into their systems.

Start with training your teams, auditing existing SOPs, and integrating CAPA workflows into your QMS. Because a deviation unlinked is a problem unchecked ⚠️.

Why CAPA is essential for excursion management:

Temperature or humidity excursions during storage, transport, or chamber operation can compromise the validity of a stability study. If not properly addressed, these deviations may impact product quality and create regulatory risk. A CAPA (Corrective and Preventive Action) system ensures that such events are systematically logged, investigated, resolved, and prevented from recurrence.

Using CAPA for stability excursions demonstrates proactive quality oversight and builds confidence in the reliability of stability data.

Consequences of unmanaged or undocumented excursions:

Regulatory agencies require documented evidence of how any deviation was evaluated and resolved. If excursions go uninvestigated or unresolved, inspectors may question the entire stability data set. This can delay submissions, require re-testing, or even lead to withdrawal of product approval if excursions are found to be critical and unmitigated.

Regulatory and Technical Context:

GMP and ICH guidelines on deviation handling:

ICH Q1A(R2) highlights the importance of maintaining specified conditions during stability testing. WHO TRS 1010 and 21 CFR 211.100-211.192 require pharmaceutical manufacturers to implement systems for corrective and preventive actions. CAPA records are often reviewed during inspections, especially in relation to stability deviations, excursions, or OOS results.

Agencies expect transparent traceability and root cause-driven action plans for any breach in defined study conditions.

Audit implications and lifecycle documentation:

CAPA documentation is crucial for audit readiness. Inspectors typically request CAPA logs when stability chambers malfunction, samples are exposed to ambient conditions, or temperature loggers show out-of-range values. The absence of documented CAPA analysis can be cited as a major non-conformance in audit reports.

Best Practices and Implementation:

Integrate excursion tracking into the CAPA framework:

Use deviation forms or electronic quality systems to initiate a CAPA whenever an excursion is detected in a stability chamber, refrigerator, freezer, or transport container. Log the following:

• Date and duration of excursion
• Chamber or device ID
• Samples affected and time points
• Root cause analysis
• Immediate containment actions

Assign clear responsibilities and timelines for investigation closure and action plan implementation.

Analyze impact and determine sample validity:

Evaluate whether the excursion exceeded acceptable thresholds (e.g., ±2°C for more than 30 minutes). Conduct a stability impact assessment—review historical degradation trends, compare with excursion duration, and decide whether the sample can be tested, quarantined, or discarded. Update the protocol or summary with findings.

Document the scientific rationale used to accept or reject the sample results post-excursion.

Implement preventive actions and QA oversight:

Preventive actions may include revalidating temperature loggers, enhancing alarm systems, retraining staff, or installing backup power supplies. Incorporate excursion learnings into SOPs and team training programs. QA should review all CAPA closures to confirm completeness, effectiveness, and recurrence mitigation.

Use CAPA trends to identify systemic issues—like frequent sensor failures or procedural lapses—and prioritize long-term solutions.